Compare Pfizer Inc (PFE) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Schwab US Large Cap Growth ETF — how do they compare? Pfizer Inc trades at $28.11 (market cap $158.56B), while Schwab US Large Cap Growth ETF trades at $36.61 (market cap $65.01B). The key difference: Pfizer Inc is far larger — about 2.4× Schwab US Large Cap Growth ETF's market cap, and Pfizer Inc pays a 6.18% dividend while Schwab US Large Cap Growth ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Schwab US Large Cap Growth ETF for 50 Days on average.
| PFE | SCHG | |
|---|---|---|
Market Cap | $158.56B | $65.01B |
Volume | 44,138,282 | 8,554,399 |
Sector | Health | Sector/Thematic |
52-Week High | $29.02 | $36.93 |
52-Week Low | $23.67 | $28.10 |
Typical Hold Time | 158 Days | 50 Days |
Enterprise Value | $210.06B | — |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
SCHG trades at $36.87, down 0.16% with a bullish technical outlook from moving averages but bearish oscillators. The ETF maintains strong growth exposure with low expense ratios, though recent news highlights concentration risks in top holdings. Dividend activity remains minimal with a $0.04 distribution scheduled for September 2026.
Growth ETF positioning favors long-term investors despite near-term overbought signals. Key risks include heavy concentration in megacap tech stocks and potential valuation compression. Analyst sentiment remains positive for strategic allocations to large-cap growth exposure with disciplined entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
